Arcadia Biosciences Reports Q3 2025 Revenue Decline but Achieves Net Income Improvement

Arcadia Biosciences, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $1.3 million, a decrease of 15% from $1.5 million in the same period last year. The decline in revenue was primarily attributed to the absence of sales from GLA oil, which contributed $217,000 in the prior year. Despite the drop in revenue, the company achieved a net income of $856,000, a significant improvement compared to a net loss of $1.6 million in the third quarter of 2024. This positive shift was driven by reduced operating expenses, which fell by 26% to $2.5 million, compared to $3.3 million in the previous year.

For the nine months ending September 30, 2025, Arcadia reported total revenues of $4.0 million, a slight increase of 3% from $3.8 million in the same period of 2024. The growth in revenue was primarily due to a 26% increase in sales of Zola coconut water, which offset the absence of GLA oil sales. Operating expenses for the nine-month period decreased by 2% to $5.1 million, with notable reductions in selling, general, and administrative expenses, which dropped by 22% to $5.4 million. The company recorded a net loss of $1.0 million for the nine months, a substantial improvement from a loss of $3.0 million in the prior year.

Significant strategic developments included the sale of the GoodWheat brand to Above Food Corp. in May 2024 for $3.7 million, which has been classified as a discontinued operation. This sale allowed Arcadia to monetize its intellectual property and streamline its focus on the Zola brand. Additionally, the company entered into a License Termination and Patent Non-Assert Agreement with Bioseed Research India, eliminating a $1.0 million contingent liability from its balance sheet. Arcadia also recorded a gain of $750,000 from the sale of certain soy traits to Bioceres Crop Solutions Corp. in March 2025.

As of September 30, 2025, Arcadia's total assets stood at $8.6 million, down from $13.5 million at the end of 2024, primarily due to a decrease in cash and cash equivalents, which fell to $1.1 million from $4.2 million. The company reported current liabilities of $2.3 million, down from $2.6 million at the end of the previous year. The accumulated deficit increased to $279.9 million, reflecting ongoing operational challenges. The company’s cash flow from operating activities showed improvement, with a net cash used of $3.9 million for the nine months ended September 30, 2025, compared to $7.4 million in the same period of 2024.

Looking ahead, Arcadia expressed concerns regarding its liquidity, indicating that its existing cash and cash equivalents may not be sufficient to meet anticipated cash requirements for at least the next 12 months. The company is exploring options for additional funding, including potential equity or debt financing, to support its operations and marketing efforts. The uncertainty surrounding the repayment of the promissory note from Above Food, which has not made its first payment, adds to the financial challenges facing the company.